Insmed (INSM)

Insmed’s commercial respiratory portfolio includes Arikayce and Brinsupri. Arikayce is an inhaled liposomal amikacin product used in a difficult-to-treat lung infection setting, reflecting the company’s focus on specialised respiratory conditions rather than broad primary-care markets. Brinsupri is also part of the respiratory franchise. Revenue is generated primarily in the United States, although the company’s addressable markets and development ambitions extend beyond a single geography.

The pipeline includes TPIP, INS1148, brensocatib and INS1201, with programmes spanning different therapeutic areas. Insmed’s research strategy includes multiple scientific approaches, such as gene therapy, protein engineering supported by artificial intelligence, protein manufacturing capabilities, RNA end-joining and synthetic rescue. This gives the company a broader technology base than a single-product biotechnology developer, while still keeping its commercial emphasis on rare and serious disorders.

For investors, Insmed is a specialty biopharma company whose valuation is shaped by product uptake, clinical trial results, regulatory milestones, reimbursement, manufacturing execution and the size of the patient populations it can serve. Its distinctive position comes from pairing a revenue-generating rare-disease respiratory business with a pipeline aimed at conditions that require targeted, high-value therapies rather than mass-market medicines.